http://orcid.org/0000-0003-3257-2540
Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Alessandro Rizzo & Angela Dalia Ricci. (2022) Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opinion on Investigational Drugs 31:6, pages 549-555.
Read now
Read now
Alessandro Rizzo & Angela Dalia Ricci. (2022) PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opinion on Investigational Drugs 31:4, pages 415-423.
Read now
Read now
Maaz Tahir Sadiq, Juliette Servante & Srinivasan Madhusudan. (2021) Precision medicine for the treatment of triple negative breast cancer: opportunities and challenges. Expert Review of Precision Medicine and Drug Development 6:4, pages 259-270.
Read now
Read now
Sun Young Oh, Shafia Rahman & Joseph A. Sparano. (2021) Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. Expert Opinion on Pharmacotherapy 22:8, pages 981-1003.
Read now
Read now
Jieya Shao. (2020) Ser784 phosphorylation: a clinically relevant enhancer of VCP function in the DNA damage response. Molecular & Cellular Oncology 7:5.
Read now
Read now
Pauline Douglas, Ruiqiong Ye, Suraj Radhamani, Alexander Cobban, Nicole P. Jenkins, Edward Bartlett, Jonathan Roveredo, Arminja N. Kettenbach & Susan P. Lees-Miller. (2020) Nocodazole-Induced Expression and Phosphorylation of Anillin and Other Mitotic Proteins Are Decreased in DNA-Dependent Protein Kinase Catalytic Subunit-Deficient Cells and Rescued by Inhibition of the Anaphase-Promoting Complex/Cyclosome with proTAME but Not Apcin. Molecular and Cellular Biology 40:13.
Read now
Read now
Siqing Fu, Yudong Wang, Khandan Keyomarsi & Funda Meric-Bernstein. (2018) Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opinion on Investigational Drugs 27:9, pages 741-751.
Read now
Read now
Yang Yang, Yanzhe Gao, Anastasia Zlatanou, Satoshi Tateishi, Vyacheslav Yurchenko, Igor B. Rogozin & Cyrus Vaziri. (2018) Diverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis. Cell Cycle 17:7, pages 833-843.
Read now
Read now
Articles from other publishers (60)
Chihiro Emori, Zachary BoucherEwelina Bolcun-Filas. (2023) CHEK2 signaling is the key regulator of oocyte survival after chemotherapy. Science Advances 9:42.
Crossref
Crossref
Qi Li, Wenyuan Qian, Yang Zhang, Lihong Hu, Shuhui Chen & Yuanfeng Xia. (2023) A new wave of innovations within the DNA damage response. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Beatriz Hernández-Suárez, David A. Gillespie, Ewa Dejnaka, Piotr Kupczyk, Bożena Obmińska-Mrukowicz & Aleksandra Pawlak. (2023) Studying the DNA damage response pathway in hematopoietic canine cancer cell lines, a necessary step for finding targets to generate new therapies to treat cancer in dogs. Frontiers in Veterinary Science 10.
Crossref
Crossref
Yunxin Duan, Lili Zhuang, Yerong Xu, Haodong Cheng, Jiawei Xia, Tao Lu & Yadong Chen. (2023) Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors. Bioorganic Chemistry 136, pages 106535.
Crossref
Crossref
Xianzhe Yu, Lingling Zhu, Ting Wang, Lu Li, Jiewei Liu, Guowei Che & Qinghua Zhou. (2023) Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:4, pages 188910.
Crossref
Crossref
Yuri Tozaki, Hiromasa Aoki, Rina Kato, Kohki Toriuchi, Saki Arame, Yasumichi Inoue, Hidetoshi Hayashi, Eiji Kubota, Hiromi Kataoka & Mineyoshi Aoyama. (2023) The Combination of ATM and Chk1 Inhibitors Induces Synthetic Lethality in Colorectal Cancer Cells. Cancers 15:3, pages 735.
Crossref
Crossref
Yiming Chang, Zhiyuan Huang, Hong Quan, Hui Li, Shuo Yang, Yifei Song, Jian Wang, Jian Yuan & Chenming Wu. (2023) Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. Frontiers in Oncology 12.
Crossref
Crossref
Randy Y.C. Poon. 2023. Encyclopedia of Cell Biology. Encyclopedia of Cell Biology
210
216
.
Xiaopeng Peng, Wanyi Pan, Feng Jiang, Weiming Chen, Zetao Qi, Weijie Peng & Jianjun Chen. (2022) Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. Pharmacological Research 186, pages 106529.
Crossref
Crossref
Abbas Ali Hosseinpour Feizi, Sajjad Vakili-Samiani, Vahid Karpisheh, Ali Masjedi, Sepideh Izadi, Sara Adibfar, Afshin Nikkhoo, Mohammad Hojjat-Farsangi, Fatemeh Atyabi, Omid Joodi khanghah, Ali Akbar Movassaghpour, Saeed Solali, Mehdi Yousefi & Farhad Jadidi-Niaragh. (2022) Increased susceptibility to doxorubicin-induced cell death in acute lymphocytic leukemia cells by inhibiting serine/threonine WEE1 kinase expression using the chitosan-carboxymethyl dextran-polyethylene glycol-TAT nanoparticles. Journal of Drug Delivery Science and Technology 77, pages 103868.
Crossref
Crossref
Joseph S. Baxter, Diana Zatreanu, Stephen J. Pettitt & Christopher J. Lord. (2022)
Resistance to
DNA
repair inhibitors in cancer
. Molecular Oncology 16:21, pages 3811-3827.
Crossref
Crossref
Erika Durinikova, Nicole M. Reilly, Kristi Buzo, Elisa Mariella, Rosaria Chilà, Annalisa Lorenzato, João M. L. Dias, Gaia Grasso, Federica Pisati, Simona Lamba, Giorgio Corti, Andrea Degasperi, Carlotta Cancelliere, Gianluca Mauri, Pietro Andrei, Michael Linnebacher, Silvia Marsoni, Salvatore Siena, Andrea Sartore-Bianchi, Serena Nik-Zainal, Federica Di Nicolantonio, Alberto Bardelli & Sabrina Arena. (2022) Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. Clinical Cancer Research 28:17, pages 3874-3889.
Crossref
Crossref
Gabriella D’Orazi & Mara Cirone. (2022) Interconnected Adaptive Responses: A Way Out for Cancer Cells to Avoid Cellular Demise. Cancers 14:11, pages 2780.
Crossref
Crossref
Saiama N. Waqar, Clifford Robinson, Anthony J. Olszanski, Alexander Spira, Melissa Hackmaster, Luisa Lucas, Laura Sponton, Hulin Jin, Ursula Hering, Damien Cronier, Marianna Grinberg, Annick Seithel-Keuth, Ivan Diaz-Padilla & Jordan Berlin. (2022) Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. Investigational New Drugs 40:3, pages 596-605.
Crossref
Crossref
Luisa Maresca, Barbara Stecca & Laura Carrassa. (2022) Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Cells 11:9, pages 1466.
Crossref
Crossref
Binbin Cheng, Wei Pan, Yi Xing, Yao Xiao, Jianjun Chen & Zheng Xu. (2022) Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. European Journal of Medicinal Chemistry 230, pages 114109.
Crossref
Crossref
Dimitra T. Stefanou, Vassilis L. Souliotis, Roubini Zakopoulou, Michalis Liontos & Aristotelis Bamias. (2021) DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?. Biomedicines 10:1, pages 82.
Crossref
Crossref
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, Giorgio Frega, Andrea Palloni, Simona Tavolari & Giovanni Brandi. (2021) Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?. Frontiers in Oncology 11.
Crossref
Crossref
Xiaohui Wu, Haijia Tang, Wen-Hao Xu, Haidan Tang, Shiyin Wei, Aihetaimujiang Anwaier, Haineng Huang, Yuan-Yuan Qu, Hailiang Zhang, Shuai Zhao, Hui Li, Wangrui Liu, Hongjing Chen, Chen Ding & Dingwei Ye. (2021) Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma. Frontiers in Genetics 12.
Crossref
Crossref
Shuai Zhao, Cuicui Wei, Haijia Tang, Han Ding, Bing Han, Shuxian Chen, Xiaoling Song, Qiang Gu, Yichi Zhang, Wangrui Liu & Jian Wang. (2021) Elevated DNA Polymerase Delta 1 Expression Correlates With Tumor Progression and Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma. Frontiers in Oncology 11.
Crossref
Crossref
Lawrence David Mason, Suresh Chava, Kiran Kumar Reddi & Romi Gupta. (2021) The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis. Cancers 13:21, pages 5516.
Crossref
Crossref
Yue Pan, Kun Li, Xufeng Tao, Ning Li, Jing Huang, Jianzhou Liu & Gary Guishan Xiao. (2021) MicroRNAs in Pancreatic Cancer and Chemoresistance. Pancreas 50:10, pages 1334-1342.
Crossref
Crossref
Peter H. Goff, Rashmi Bhakuni, Thomas Pulliam, Jung Hyun Lee, Evan T. Hall & Paul Nghiem. (2021) Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers 13:14, pages 3415.
Crossref
Crossref
Parnia Rahnamay Farnood, Romina Danesh Pazhooh, Zatollah Asemi & Bahman Yousefi. (2021) DNA damage response and repair in pancreatic cancer development and therapy. DNA Repair 103, pages 103116.
Crossref
Crossref
Eva-Maria Faulhaber, Tina Jost, Julia Symank, Julian Scheper, Felix Bürkel, Rainer Fietkau, Markus Hecht & Luitpold V. Distel. (2021) Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells. Genes 12:6, pages 925.
Crossref
Crossref
Shuang Wang, Minghui Wei & Weiyu Zhu. (2021) Melatonin increases doxorubicin-induced apoptosis via oxidative DNA damage in oral squamous cell carcinoma. DNA Repair, pages 103154.
Crossref
Crossref
Husheng Ding, Nicole D. Vincelette, Cordelia D. McGehee, Mira A. Kohorst, Brian D. Koh, Annapoorna Venkatachalam, X. Wei Meng, Paula A. Schneider, Karen S. Flatten, Kevin L. Peterson, Cristina Correia, Sun-Hee Lee, Mrinal Patnaik, Jonathan A. Webster, Gabriel Ghiaur, B. Douglas Smith, Judith E. Karp, Keith W. Pratz, Hu Li, Larry M. Karnitz & Scott H. Kaufmann. (2021) CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia. Cancer Research 81:10, pages 2666-2678.
Crossref
Crossref
María Guadalupe Cupido-Sánchez, Norma Estela Herrera-González, Columba Citlalli Barrera Mendoza, María Luisa Morales Hernández & Eva Ramón-Gallegos. (2021) In silico analysis of the association of hsa-miR-16 expression and cell survival in MDA-MB-231 breast cancer cells subjected to photodynamic therapy. Photodiagnosis and Photodynamic Therapy 33, pages 102106.
Crossref
Crossref
Linda van Bijsterveldt, Samuel C. Durley, Tim S. Maughan & Timothy C. Humphrey. (2021) The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors. Clinical Cancer Research 27:4, pages 937-962.
Crossref
Crossref
Alessandro Rizzo & Giovanni Brandi. (2021) Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treatment and Research Communications 27, pages 100328.
Crossref
Crossref
Kyung Yong Lee & Anindya Dutta. (2021) Chk1 promotes non-homologous end joining in G1 through direct phosphorylation of ASF1A. Cell Reports 34:4, pages 108680.
Crossref
Crossref
Fei Li, Zheng‐Ze Shen, Chao‐Ming Xiao & Qian‐Kun Sha. (2020) YY1‐mediated up‐regulation of lncRNA LINC00466 facilitates glioma progression via miR‐508/CHEK1. The Journal of Gene Medicine 23:1.
Crossref
Crossref
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak & Aneta Rogalska. (2020) Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Monika Joshi, Petros Grivas, Amir Mortazavi, Paul Monk, Steven K. Clinton, Michele Sue‐Ann Woo, Sheldon L. Holder, Joseph J. Drabick & Ming Yin. (2020) Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer. Cancer Medicine 9:24, pages 9365-9372.
Crossref
Crossref
Andreas Seeber, Kai Zimmer, Florian Kocher, Alberto Puccini, Joanne Xiu, Chadi Nabhan, Andrew Elliott, Richard M Goldberg, Axel Grothey, Anthony F Shields, Francesca Battaglin, Wafik S El-Deiry, Philip A Philip, John L Marshall, Michael Hall, W Michael Korn, Heinz-Josef Lenz, Dominik Wolf, Clemens Feistritzer & Gilbert Spizzo. (2020)
Molecular characteristics of
BRCA1/2
and
PALB2
mutations in pancreatic ductal adenocarcinoma
. ESMO Open 5:6, pages e000942.
Crossref
Crossref
Young Hwa Soung, Heesung Chung, Cecilia Yan, Andrew Fesler, Hyungjin Kim, Eok-Soo Oh, Jingfang Ju & Jun Chung. (2020) Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers. Cancers 12:8, pages 2209.
Crossref
Crossref
Zhaohui Wang, Cheng Xu, Bill H. Diplas, Casey J. Moure, Chin-Pu Jason Chen, Lee H. Chen, Changzheng Du, Huishan Zhu, Paula K. Greer, Liwei Zhang, Yiping He, Matthew S. Waitkus & Hai Yan. (2020) Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. Molecular Cancer Research 18:7, pages 968-980.
Crossref
Crossref
Kristyna Tomasova, Andrea Cumova, Karolina Seborova, Josef Horak, Kamila Koucka, Ludmila Vodickova, Radka Vaclavikova & Pavel Vodicka. (2020) DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome. Cancers 12:7, pages 1713.
Crossref
Crossref
Cuige Zhu, Anna Rogers, Karama Asleh, Jennifer Won, Dongxia Gao, Samuel Leung, Shan Li, Kiran R. Vij, Jian Zhu, Jason M. Held, Zhongsheng You, Torsten O. Nielsen & Jieya Shao. (2020) Phospho-Ser784-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. Cell Reports 31:10, pages 107745.
Crossref
Crossref
Madalena Tarsounas & Patrick Sung. (2020) The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology 21:5, pages 284-299.
Crossref
Crossref
Ryan B. Jensen & Eli Rothenberg. (2020) Preserving genome integrity in human cells via DNA double-strand break repair. Molecular Biology of the Cell 31:9, pages 859-865.
Crossref
Crossref
Joseph Berei, Adam Eckburg, Edward Miliavski, Austin D. Anderson, Rachel J. Miller, Joshua Dein, Allison M. Giuffre, Diana Tang, Shreya Deb, Kavya Sri Racherla, Meet Patel, Monica Saravana Vela & Neelu Puri. (2020) Potential Telomere-Related Pharmacological Targets. Current Topics in Medicinal Chemistry 20:6, pages 458-484.
Crossref
Crossref
Masahiro Uehara, Tetsuro Kusaba, Tomoharu Ida, Kunihiro Nakai, Tomohiro Nakata, Aya Tomita, Noriko Watanabe-Uehara, Kisho Ikeda, Takashi Kitani, Noriyuki Yamashita, Yuhei Kirita, Satoaki Matoba, Benjamin D. Humphreys & Keiichi Tamagaki. (2020) Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice. Scientific Reports 10:1.
Crossref
Crossref
Dean G. Brown, James Shorter & Heike J. Wobst. (2020) Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia. Bioorganic & Medicinal Chemistry Letters 30:4, pages 126942.
Crossref
Crossref
Kevin J. Lee, Elise Mann, Griffin Wright, Cortt G. Piett, Zachary D. Nagel & Natalie R. Gassman. (2020) Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. Therapeutic Advances in Medical Oncology 12, pages 175883592095835.
Crossref
Crossref
Hannah L. Smith, Harriet Southgate, Deborah A. Tweddle & Nicola J. Curtin. (2020) DNA damage checkpoint kinases in cancer. Expert Reviews in Molecular Medicine 22.
Crossref
Crossref
Qi Liu, Jinlan Gao, Chenyang Zhao, Yingying Guo, Shiquan Wang, Fei Shen, Xuesha Xing & Yang Luo. (2020) To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response. DNA Repair 85, pages 102702.
Crossref
Crossref
Shuaishuai Xu, Huaxiang Xu, Wenquan Wang, Shuo Li, Hao Li, Tianjiao Li, Wuhu Zhang, Xianjun Yu & Liang Liu. (2019) The role of collagen in cancer: from bench to bedside. Journal of Translational Medicine 17:1.
Crossref
Crossref
Yansong Bian, Yaroslav Teper, Lesley A. Mathews Griner, Taylor J. Aiken, Vivek Shukla, Rajarshi Guha, Paul Shinn, Hong-Wu Xin, Holger Pflicke, Astin S. Powers, Dandan Li, Jian-kang Jiang, Paresma Patel, Steven A. Rogers, Jeffrey Aubé, Marc Ferrer, Craig J. Thomas & Udo Rudloff. (2019) Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype. Molecular Cancer Therapeutics 18:11, pages 2097-2110.
Crossref
Crossref
Yuanqiang Wang, Haiqiong Guo, Zhiwei Feng, Siyi Wang, Yuxuan Wang, Qingxiu He, Guangping Li, Weiwei Lin, Xiang-Qun Xie & Zhihua Lin. (2019) PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance. Molecules 24:20, pages 3784.
Crossref
Crossref
Jonathan A Ledermann. (2019) Extending the scope of PARP inhibitors in ovarian cancer. The Lancet Oncology 20:4, pages 470-472.
Crossref
Crossref
Jingxin Ma, Xiaopeng Hu, Chenghui Liao, Haitao Xiao, Qinchang Zhu, Ying Li, Zhigang Liu, Anjin Tao, Zhendan He, Chenshu Xu & Kai Zheng. (2019) Gypenoside L Inhibits Proliferation of Liver and Esophageal Cancer Cells by Inducing Senescence. Molecules 24:6, pages 1054.
Crossref
Crossref
Nisha Pillay, Anthony Tighe, Louisa Nelson, Samantha Littler, Camilla Coulson-Gilmer, Nourdine Bah, Anya Golder, Bjorn Bakker, Diana C.J. Spierings, Dominic I. James, Kate M. Smith, Allan M. Jordan, Robert D. Morgan, Donald J. Ogilvie, Floris Foijer, Dean A. Jackson & Stephen S. Taylor. (2019) DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors. Cancer Cell 35:3, pages 519-533.e8.
Crossref
Crossref
Amirali B. Bukhari, Cody W. Lewis, Joanna J. Pearce, Deandra Luong, Gordon K. Chan & Armin M. Gamper. (2019) Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis. Journal of Clinical Investigation 129:3, pages 1329-1344.
Crossref
Crossref
Keith H. Jansson, John B. Tucker, Lauren E. Stahl, John K. Simmons, Caitlyn Fuller, Michael L. Beshiri, Supreet Agarwal, Lei Fang, Paul G. Hynes, Aian Neil Alilin, Ross Lake, Yasmine C. Abbey, Jacob Cawley, Caitlin M. Tice, JuanJuan Yin, Crystal McKnight, Carleen Klummp-Thomas, Xiaohu Zhang, Rajarshi Guha, Shelley Hoover, R. Mark Simpson, Holly M. Nguyen, Eva Corey, Craig J. Thomas, David A. Proia & Kathleen Kelly. (2018) High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Scientific Reports 8:1.
Crossref
Crossref
Xu-lei Sun, Hao Jiang, Dong-xu Han, Yao Fu, Jian-bo Liu, Yan Gao, Shu-min Hu, Bao Yuan & Jia-bao Zhang. (2018) The activated DNA double-strand break repair pathway in cumulus cells from aging patients may be used as a convincing predictor of poor outcomes after in vitro fertilization-embryo transfer treatment. PLOS ONE 13:9, pages e0204524.
Crossref
Crossref
Anke E.M. van Erp, Yvonne M.H. Versleijen-Jonkers, Winette T.A. van der Graaf & Emmy D.G. Fleuren. (2018) Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma. Molecular Cancer Therapeutics 17:7, pages 1365-1380.
Crossref
Crossref
Ben Davidson, Marianne Bjørnerem, Arild Holth, Ellen Hellesylt, Thea E. Hetland Falkenthal & Vivi Ann Flørenes. (2018) Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma. Gynecologic Oncology 150:1, pages 136-142.
Crossref
Crossref
Anu Prakash, Juan Garcia-Moreno, James Brown & Emer Bourke. (2018) Clinically Applicable Inhibitors Impacting Genome Stability. Molecules 23:5, pages 1166.
Crossref
Crossref
Ingrid M. E. Desar, Emmy D. G. Fleuren & Winette T. A. van der Graaf. (2018) Systemic Treatment for Adults with Synovial Sarcoma. Current Treatment Options in Oncology 19:2.
Crossref
Crossref